

1 **The Seasonal Influenza Vaccine Cannot Trigger a Titer Increase Among** 2 **Some Elderly Individuals**

3
4 Authors

5 Yang Ge^{1^*}, Wangnan Cao^{2*}, Shengzhi Sun³, Ted M. Ross^{4,5}, Ye Shen^{6^}

6 Authors affiliations

7 ¹: School of Health Professions, University of Southern Mississippi, Hattiesburg, 39402,
8 MS, USA; <https://orcid.org/0000-0001-5100-0703>; ²: School of Public Health, Peking
9 University, Beijing, China; ³: School of Public Health, Capital Medical University, Beijing,
10 China; ⁴: Center for Vaccines and Immunology, The University of Georgia, Athens, 30606,
11 GA, USA; ⁵: Cleveland Clinic, Port St. Lucie, 34952, FL, USA; ⁶: College of Public Health, The
12 University of Georgia, Athens, 30606, GA, USA; <https://orcid.org/0000-0002-6662-0048>.

13 * Joint first authors

14 ^ Corresponding authors: yang.ge@usm.edu, yeshen@uga.edu

15 Abstract word count: 47

16 Text word count: 1076

17 **Conflicts of interest:** None of the authors declare any conflicts of interest.

18 **Funding sources:** Yang Ge was supported by the Start-up Grant from the University of
19 Southern Mississippi and NIH contract 75N93019C00052. Wangnan Cao was supported
20 by Beijing Natural Science Foundation (L222029). Ted M. Ross is supported by the Georgia

21 Research Alliance as an Eminent Scholar. Ye Shen received partial support from NIH
22 grants/contracts R35GM146612, R01AI170116 and 75N93019C00052. The funders had no
23 role in the study design, data collection and analysis, decision to publish, or preparation
24 of the manuscript.

25 **Ethics statement:** We conducted a secondary analysis on data collected from an ongoing
26 human vaccine cohort study. The procedures, informed consent, and data collection
27 documents of the cohort study were reviewed and approved by the Western Institutional
28 Review Board and the Institutional Review Boards of the University of Pittsburgh and the
29 University of Georgia.

30 **Acknowledgements:** The authors would like to thank Hannah Hanley for coordinating
31 the UGA influenza vaccine study, as well as Brittany Baker, Frankie Stewart, and Emma
32 Whitesell for excellent phlebotomy and data entry services. The authors would also like
33 to thank Hana Ji, James Allen, Michael Carlock, Jasmine Burris, Omar Hamwy, Mitchell Lee,
34 Laruen Howland for processing samples and Rosemary Kim, Jasper Gattiker, and Erin
35 Jarrett for performing and virological assays. The authors also thank Brad Phillips and Kim
36 Schmitz from the UGA Clinical and Translation Research Unit for assistance in enrollment
37 and sample collections. Finally, the authors thank all the enrolled participants for
38 providing their time and samples to the study.

39

40

Abstract

41 Many elderly exhibited absent responses to influenza vaccines. Our exploration of this
42 heterogeneity revealed associations with vaccine dose (HD vs. SD, OR: 0.59 (95%CrI, 0.4
43 to 0.87)), pre-vaccination titer levels (OR: 1.57 (95%CrI, 1.38 to 1.8), and gender (Male
44 vs. Female OR: 2.12 (95%CrI, 1.38 to 3.25)).

45 **Key words:** Influenza, Vaccine, Titer Increase

46 **Data Availability Statement:** The data supporting the findings of this study are
47 available upon reasonable request.

48

Main text

49 Influenza results in over half a million deaths annually, predominantly among older adults
50 [1,2]. Certain older individuals exhibit a limited or absent response to vaccines, while
51 others do not. Investigating the factors contributing to this disparity can enhance our
52 comprehension of high-risk populations and facilitate the enhancement of vaccination
53 strategies.

54

55 According to CDC's recommendations [3], adults aged 65 years and older have the option
56 to choose a high-dose (HD) influenza vaccine over a standard-dose (SD) one. The licensed
57 SD split-inactivated virion vaccine contains 15 micrograms of HA antigen for each strain.
58 In contrast, Sanofi Pasteur's Fluzone HD provides 60 micrograms of HA for each vaccine
59 strain, showing a relative benefit [4]. It would be intriguing to explore this benefit further,
60 investigating whether the HD vaccine reduces the proportion of older adults with a limited
61 or absent response to vaccines or merely enhances antibody levels in those who respond.

62

63 We obtained human vaccination data covering the flu seasons from 2014/15 to 2019/20
64 from our ongoing vaccination cohort study [5,6]. Each year, investigators enrolled
65 individuals who hadn't received an influenza vaccine in the season preceding the flu
66 season's onset. People aged 65 and older were offered a choice between HD and SD
67 vaccines. Serological samples were collected both before vaccination and 21-28 days

68 after. Hemagglutination-inhibition (HAI) antibody levels were assessed using standard
69 dilution assays. Thus, the data has hierarchical features, with individuals repeatedly
70 enrolled in different flu seasons and tested for HAI titers for different homologous strains.
71 The HD vaccine was trivalent during the entire study years, while the SD vaccines were
72 trivalent in 2013 and 2014, but quadrivalent in later years, with the quadrivalent
73 formulation containing an additional B-strain. Unlike the SD, the trivalent HD vaccine
74 contained only a single B strain; therefore, in this study, we focused solely on influenza A
75 subtypes and excluded results related to all B strains. Our emphasis was on the
76 homologous HAI titer increase of the vaccine. It was defined as log₂ scale of the ratio of
77 the post-vaccination Hemagglutination Inhibition (HAI) titer over the pre-vaccination HAI
78 titer. This outcome signifies the difference between post-vaccination and pre-vaccination
79 titers, providing insight into a participant's immunological response to the vaccine.

80
81 The HAI titer, obtained through the dilution assay, exhibited discrete positive values,
82 resulting in discrete observations of titer increase. However, a significant number of
83 participants showed no titer increase after vaccination, leading to an excess of zeros and
84 overdispersion in the outcome of titer increase. To address this, we assumed the elderly
85 could be categorized into two sub-populations. The first, **Sensitive to the Influenza**
86 **Vaccine (SIV)**, included participants with a positive vaccine-induced titer increase. The
87 other, **Insensitive to the Influenza Vaccine (IIV)**, displayed either zero or negative titer

88 increase. The HAI titer, obtained through the dilution assay, had discrete positive values,
89 leading to discrete observations of titer increase. Thus, we applied a hurdle Poisson
90 regression model to our data.

91
92 Our hurdle Poisson regression model combines a logistic and Poisson process. The logistic
93 process generates zero to represent the IIV sub-population, characterized by zero or
94 negative titer increase. When the logistic process yields one (representing the SIV sub-
95 population), the Poisson process is used to model the positive values of titer increase. If
96 we define θ as the probability of IIV and λ as the titer increase for SIV, the probability
97 mass function of the hurdle-Poisson model is defined by

$$98 \quad p(y|\theta, \lambda) = \begin{cases} \theta & \text{if } y = 0, \text{ and} \\ (1 - \theta) \frac{\text{Poisson}(y|\lambda)}{1 - \text{PoissonCDF}(0|\lambda)} & \text{if } y > 0, \end{cases}$$

99
100 To assess the vaccine dose impact (HD vs. SD) while accounting for multilevel features in
101 the study, we used a Bayesian multilevel modeling approach. This included incorporating
102 two random intercepts for repeated enrollment and strains formulated into a single
103 vaccine. Our models also considered age, gender, race, and pre-vaccination titer as
104 covariates. We use mean and credible interval (CrI) to summarize results.

105

106 Our samples cover influenza seasons from 2013/14 to 2019/20. During this time, the HD
107 and SD vaccines were given for 564 and 440 times, respectively, to individuals aged 65
108 years and older (Figure 1A). Both vaccine groups had comparable age and gender
109 distributions, along with similar median pre-vaccination titers below 1:40. Across the
110 entire study period, eight different influenza type A vaccine strains were observed. About
111 one-third of the elderly population did not show a positive titer increase after vaccination,
112 ranging from 6% to 53% (Figure 1B).


113
114 The results of the hurdle-Poisson model are shown in Figure 1C. In comparison to the SD,
115 individuals who received the HD vaccine had an Odds Ratio (OR) of being an IIV as 0.59
116 (95%CrI, 0.4 to 0.87). Additionally, higher pre-vaccination titer and being male had ORs
117 equal to 1.57 (95%CrI, 1.38 to 1.8) and 2.12 (95%CrI, 1.38 to 3.25), respectively. In cases
118 where an individual responded to the influenza vaccine, HD might associate with a small
119 additional titer increase as 0.08 (95%CrI, -0.07 to 0.22). Conversely, higher pre-vaccination
120 titer and being male were associated with a reduced titer increase as -0.23 (95%CrI, -0.28
121 to -0.18) and -0.24 (95%CrI, -0.4 to -0.07), respectively.

122
123 Influenza vaccine effectiveness varies among populations, showing significantly reduced
124 protection (10%) among the elderly [7]. An important reason could be aligned with our
125 findings that many elderly individuals (> 30%) had limited or absent immune responses

126 after vaccination. Our study suggests that the HD vaccine may decrease the likelihood of
127 an elderly individual becoming an IIV, but it has only a mild impact on the actual titer
128 increase if a response is triggered. We also observed that individuals with some pre-
129 existing immunities or being male had a worse response to the vaccine than their
130 counterparts.

131
132 Our study controlled for repeated influenza vaccination and the administration of multiple
133 strains simultaneously in trivalent or quadrivalent vaccines. However, our sample size was
134 not balanced across the seven influenza seasons, and participants were not randomly
135 assigned to HD or SD groups, potentially introducing bias. Additionally, we were not able
136 to further explore why some individuals did not adequately respond to the vaccine due
137 to a lack of detailed health background information.

138
139 Understanding the mechanism behind how individuals become the IIV population poses
140 a significant challenge, but it is crucial for the development of a universal influenza vaccine
141 [8]. If an influenza vaccine only works on the low-risk population and cannot induce an
142 immune response in high-risk populations (e.g., the elderly), our fight against the impact
143 of the flu remains challenging and arduous. Additional research is warranted to study why
144 the influenza vaccine cannot trigger a titer increase among some elderly individuals.



145

146 Figure 1: Data description and hurdle-poisson model outputs. A) Data description; B)

147 The distribution of titer increase for different vaccine strains. The proportions of Elderly

148 sub-population were insensitive to the influenza vaccine (IIV) has been calculated. C)

149 Estimates of the hurdle-poisson model. The left side is the logistic model for estimating

150 the associations between variables and the likelihood of being an IIV individual. The

151 right side is the Poisson model for estimating the associations between variables and

152 the titer increase for an SIV individual.

153

154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173

Reference

[1] Iuliano AD, Roguski KM, Chang HH, et al. [Estimates of global seasonal influenza-associated respiratory mortality: A modelling study](#). *The Lancet*. 2018;391:1285–1300.

[2] Thompson WW, Shay DK, Weintraub E, et al. [Mortality associated with influenza and respiratory syncytial virus in the United States](#). *JAMA*. 2003;289:179–186.

[3] Grohskopf LA. [Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices United States, 2023 Influenza Season](#). *MMWR Recommendations and Reports*. 2023;72.

[4] van Aalst R, Gravenstein S, Mor V, et al. [Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study](#). *Vaccine*. 2020;38:372–379.

[5] Abreu RB, Clutter EF, Attari S, et al. [IgA Responses Following Recurrent Influenza Virus Vaccination](#). *Frontiers in Immunology*. 2020;11:902.

[6] Carlock MA, Ingram JG, Clutter EF, et al. [Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses](#). *Human Vaccines & Immunotherapeutics*. 2019;15:2030–2043.

[7] Price AM, Flannery B, Talbot HK, et al. [Influenza Vaccine Effectiveness Against Influenza A\(H3N2\)-Related Illness in the United States During the 2021 Influenza Season](#). *Clinical Infectious Diseases*. 2023;76:1358–1363.

- 174 [8] Erbeling EJ, Post DJ, Stemmy EJ, et al. [A Universal Influenza Vaccine: The Strategic](#)
175 [Plan for the National Institute of Allergy and Infectious Diseases](#). The Journal of
176 Infectious Diseases. 2018;218:347–354.